SCHEMBL29813404

SCHEMBL29813404

CC(C)NC(=O)Nc1nc2cc(-c3n[nH]c(=O)c4ccccc34)ccc2[nH]1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ LMNA P02545 2/20 0.62
▸ POLB P06746 2/20 0.62
▸ HPGD P15428 1/20 0.62
▸ BLM P54132 1/20 0.62
▸ ROCK1 Q13464 13/20 0.56
▸ CYP1A2 P05177 1/20 0.46
▸ MAPK1 P28482 1/20 0.44
▸ ROCK2 O75116 5/20 0.43
▸ TSHR P16473 1/20 0.42
▸ PDE4A P27815 1/20 0.42
▸ PDE4B Q07343 1/20 0.42
▸ PDE4C Q08493 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18249846 1.00 SMN1; SMN2 (0.62) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL29813235 0.89 LMNA (0.65) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL18249873 0.89 LMNA (0.65) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL18258497 0.86 LMNA (0.67) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL29813360 0.86 LMNA (0.67) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL29813330 0.86 LMNA (0.62) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL18249851 0.86 LMNA (0.62) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL18249832 0.85 LMNA (0.66) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL29813332 0.85 LMNA (0.69) SMN1; SMN2LMNAPOLBHPGDBLM
SCHEMBL18258487 0.85 LMNA (0.69) SMN1; SMN2LMNAPOLBHPGDBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298005-B1 ANTI-CANCER COMPOUNDS UNIV CALIFORNIA (US) 2024-01-24 — — EP disclosed
US-11708352-B2 Anti-cancer compounds THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-07-25 — — US disclosed
US-20220267307-A1 ANTI-CANCER COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708352-B2 Anti-cancer compounds TP53, VHL, BAD SMN1; SMN2 2063/4885LMNA 2654/4885POLB 714/4885
US-20220267307-A1 ANTI-CANCER COMPOUNDS TP53, VHL, BAD SMN1; SMN2 2063/4885LMNA 2654/4885POLB 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback